Drug Profile
Research programme: botulinum toxin therapeutics - DOR BioPharma
Latest Information Update: 28 Aug 2007
Price :
$50
*
At a glance
- Originator DOR BioPharma
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Botulism
Most Recent Events
- 21 Feb 2005 Preclinical trials in Botulism in USA (unspecified route)